FDA updates Merck's Covid-19 pill EUA and reaffirms it should only be used as a last resort
The FDA recently revised the EUA for Merck’s Covid-19 pill molnupiravir, explaining that it should only be used as a last line of defense if other treatments are available, including Pfizer’s pill Paxlovid, which posted 89% final efficacy results in the NEJM this week. Regulators also said other more highly efficacious infused drugs, including GlaxoSmithKline’s sotrovimab and Gilead’s remdesivir, should be used before molnupiravir.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters